目的：观察二甲双胍联合Folfox6治疗结直肠癌合并2型糖尿病的临床效果和安全性。方法将2007年3月至2008年8月在我院肿瘤科住院治疗的50例2型糖尿病合并结直肠癌的患者随机分成两组，二甲双胍组接受二甲双胍联合Folfox6治疗，非二甲双胍组接受其他糖尿病药物联合Folfox6治疗。结果二甲双胍组治疗总有效率为60％，非二甲双胍组治疗总有效率为36％，差异有统计学意义（P<0.05）；二甲双胍组腹泻与呕吐与非二甲双胍组相比，差异有统计学意义（P<0.05）；二甲双胍组的5年生存率显著高于非二甲双胍组，差异有统计学意义（P<0.05）。结论二甲双胍联合Folfox6能显著提高2型糖尿病合并结直肠癌患者的临床疗效，值得在临床推广应用。%Objective To explore the clinical effects and safety of metformin integrated with folfox6 treating colorectal cancer complicated with type 2 diabetes mellitus. Methods 50 cases with type 2 diabetes mellitus complicated with colorectal cancer ac-cepting treatment from March, 2007 to August, 2008 were divided randomly into two groups, the metformin group was treated with metformin as well as folfox6 while the non-metformin group was treated with other diabetes drug combined with folfox6. Results The total effective rate in the metformin group is 60%, it is statistical to compare that (36%) in the non-metformin group (P<0.05);there is also statistical meaning to compare the nausea and vomiting between the two groups (P<0.05);after 5 years of follow-up observation, the survival curve of the total cancer patients in the metformin group is higher than that of the non-metformin group, which is statistical (P<0.05). Conclusion Metformin integrated with folfox6 can improve the therapeutic effect on colorectal cancer complicated with type 2 diabetes mellitus, which worth promoting.
展开▼
